Cg Oncology Inc(CGON) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 28 at 4:10 PM ET (Korea 10/29 05:10)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -2.7 | Insider Own | 33.33% | Shs Outstand | 88.3M | Perf Week | 2.76% |
| Market Cap | 5.67B | Forward P/E | - | EPS next Y | 5.64% | Insider Trans | 1.13% | Shs Float | 59.1M | Perf Month | -9.3% |
| Enterprise Value | 4.65B | PEG | - | EPS next Q | -0.83 | Inst Own | 89.41% | Short Float | 15.02% | Perf Quarter | -12.42% |
| Income | -0.22B | P/S | 910.02 | EPS this Y | -59.51% | Inst Trans | 2.58% | Short Ratio | 10.18 | Perf Half Y | -1.22% |
| Sales | 0.01B | P/B | 5.49 | EPS next 5Y | 24.33% | ROA | -25.11% | Short Interest | 8.87M | Perf YTD | 54.05% |
| Book/sh | 11.65 | P/C | 5.51 | EPS past 3/5Y | -46.89% -65.75% | ROE | -26.41% | 52W High | -21.01% ($80.97) | Perf Year | 46.33% |
| Cash/sh | 11.6 | P/FCF | - | Sales past 3/5Y | 176.56% -20.97% | ROIC | -21.64% | 52W Low | 78.66% ($35.80) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -60.33% | Gross Margin | -93.32% | Volatility(W/M) | 4.13% 4.26% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 746.38 | Sales Y/Y TTM | 1030.31% | Oper. Margin | -4056.18% | ATR (14) | 2.72 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 22.2 | EPS Q/Q | -64.91% | Profit Margin | -3602.68% | RSI (14) | 46.27 | Recom | 1.13 |
| Dividend Gr. 3/5Y | - | Current Ratio | 22.22 | Sales Q/Q | - | SMA20 | 1.25% ($63.17) | Beta | 0.3 | Target Price | $91.08 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/8/6 | SMA50 | -8.68% ($70.04) | Rel Volume | 1.08 | Prev Close | $62.94 |
| Employees | 142 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | -35.5% 220.68% | SMA200 | -2.8% ($65.8) | Avg Volume(3M) | 0.87M | Price | $63.96 |
| IPO | 2024/1/25 | Option/Short | Yes/Yes | Trades | 7865 | Volume | 942,271 | Change | 1.62% |
🧬 A clinical-stage biotech company developing treatments for bladder cancer. Its lead candidate, cretostimogene, is being developed as an oncolytic immunotherapy for non-muscle invasive bladder cancer, administered directly into the bladder. The candidate has received Fast Track and Breakthrough Therapy designations from the U.S. Food and Drug Administration and is currently in Phase 3 clinical trials.
Over the past 1 year, roughly in the middle
21% below its 1-year high.
Traded about as much as usual. That is 108% of its average volume.
CGON has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -59.5% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $91,002. Peers typically go for $1,648.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 89.4%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #47 of 594 in the industry
Based on market cap of $6B.
FAQ
What kind of company is CGON?
CGON belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CGON?
The market cap of CGON is approximately $5.7B, ranking 1,271 within its sector.
What is the 52-week high and low for CGON?
CGON has recorded a 52-week high of $80.97 and a low of $35.80.
